Timely detection of the pathophysiological changes and cognitive impairment caused by
Alzheimer's disease (AD) is increasingly pressing because of the advent of biomarker …

While blood-based tests are readily available for various conditions, including
cardiovascular diseases, type 2 diabetes, and common cancers, Alzheimer's disease (AD) …

Abstract The National Institute on Aging and the Alzheimer's Association convened three
separate work groups in 2011 and single work groups in 2012 and 2018 to create …

Cost-effective strategies for identifying amyloid-β (Aβ) positivity in patients with cognitive
impairment are urgently needed with recent approvals of anti-Aβ immunotherapies for …

Background Recently developed blood markers for Alzheimer's disease (AD) detection have
high accuracy but usually require ultra-sensitive analytic tools not commonly available in …

Recently approved anti-amyloid immunotherapies for Alzheimer's disease (AD) require
evidence of amyloid-β pathology from positron emission tomography (PET) or cerebrospinal …

Disease staging, whereby the spatial extent and load of brain pathology are used to
estimate the severity of Alzheimer disease (AD), is pivotal to the gold-standard …

Blood biomarkers have emerged as accessible, cost-effective, and highly promising tools for
advancing the diagnostics of Alzheimer's disease. However, transitioning from cerebrospinal …

Background and objective Phosphorylated tau (p-tau) 217 has recently received attention
because it seems more reliable than other p-tau variants for identifying Alzheimer's disease …

Background Antibody-based immunoassays have enabled quantification of very low
concentrations of phosphorylated tau (p-tau) protein forms in cerebrospinal fluid (CSF) …